356 related articles for article (PubMed ID: 28110461)
1. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
Esposito A; Criscitiello C; Trapani D; Curigliano G
Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
Cheng X; Zhang L; Chen Y; Qing C
J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
4. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
Jiang T; Ren S; Zhou C
Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
[TBL] [Abstract][Full Text] [Related]
5. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.
Esposito A; Bardelli A; Criscitiello C; Colombo N; Gelao L; Fumagalli L; Minchella I; Locatelli M; Goldhirsch A; Curigliano G
Cancer Treat Rev; 2014 Jun; 40(5):648-55. PubMed ID: 24184333
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
[TBL] [Abstract][Full Text] [Related]
7. Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
Lin CC; Huang WL; Wei F; Su WC; Wong DT
Expert Rev Mol Diagn; 2015; 15(11):1427-40. PubMed ID: 26420338
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
He J; Tan W; Ma J
Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
[TBL] [Abstract][Full Text] [Related]
9. Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
Reinhardt F; Franken A; Fehm T; Neubauer H
Tumour Biol; 2017 Nov; 39(11):1010428317731511. PubMed ID: 29129161
[TBL] [Abstract][Full Text] [Related]
10. [Circulating cell-free DNA as biomarker for cancer *header*].
Isomursu A; Kononen J; Kuopio T
Duodecim; 2015; 131(5):424-32. PubMed ID: 26237904
[TBL] [Abstract][Full Text] [Related]
11. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
Vallée A; Audigier-Valette C; Herbreteau G; Merrien J; Tessonnier L; Théoleyre S; Denis MG
Lung Cancer; 2016 Jan; 91():73-4. PubMed ID: 26612314
[No Abstract] [Full Text] [Related]
12. A liquid biopsy in primary lung cancer.
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
Surg Today; 2019 Jan; 49(1):1-14. PubMed ID: 29644440
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsies in lung cancer: the new ambrosia of researchers.
Rolfo C; Castiglia M; Hong D; Alessandro R; Mertens I; Baggerman G; Zwaenepoel K; Gil-Bazo I; Passiglia F; Carreca AP; Taverna S; Vento R; Santini D; Peeters M; Russo A; Pauwels P
Biochim Biophys Acta; 2014 Dec; 1846(2):539-46. PubMed ID: 25444714
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies.
Esposito A; Criscitiello C; Locatelli M; Milano M; Curigliano G
Pharmacol Ther; 2016 Jan; 157():120-4. PubMed ID: 26615782
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
16. The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.
Huang WL; Wei F; Wong DT; Lin CC; Su WC
Biomed Res Int; 2015; 2015():340732. PubMed ID: 26448936
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Cagle PT; Capelozzi VL; Dacic S; Hariri LP; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao M; Vivero M; Yatabe Y
Arch Pathol Lab Med; 2016 Aug; 140(8):825-9. PubMed ID: 27195432
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA for personalized lung cancer monitoring.
Fiala C; Diamandis EP
BMC Med; 2017 Aug; 15(1):157. PubMed ID: 28814291
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
20. Emerging concepts in liquid biopsies.
Perakis S; Speicher MR
BMC Med; 2017 Apr; 15(1):75. PubMed ID: 28381299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
